goserelin acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  

188 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
goserelin acetate / Generic mfg.
ACTRN12613000107729: The effect of intermittent versus continuous androgen deprivation therapy in Chinese patients with advanced prostate cancer: A prospective controlled Trial from China

Active, not recruiting
4
100
 
Changhai Hospital, Second Military Medical University, Changhai hospital' s" 1255"construction plan
prostate cancer
 
 
ChiCTR-TRC-08000068: Randomized controlled study about the influence of postoperative use of GnRHa on recurrence and pregnancy rate in moderate or severe endometriosis

Recruiting
4
60
 
No intervention. Begin spontaneous pregnancy immediately after inclusion ;GnRHa (Zoladex) for 6 courses of treatment, then begin spontaneous pregnancy
Women's Hospital, School of Medicine, Zhejiang University; Level of the institution：, Self-funded
Endometriosis
 
 
2006-001909-28: Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de la recidiva bioquímica del cáncer de próstata tratado con radioterapia.

Ongoing
4
180
Europe
BUSERELINA, GOSERELINA, LEUPRORELINA, TRIPTORELINA, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL, SUPREFACT DEPOT, ZOLADEX TRIMESTRAL 10,8 mg, PROCRIN TRIMESTRAL, ELIGARD TRIMESTRAL 22,5 mg, DECAPEPTYL TRIMESTRAL
Grupo GICOR
Cáncer de próstata tratado con radioterapia y que presenta recidiva bioquímica.
 
 
2007-003137-17: Tratamiento neoadyuvante con quimioterapia (Taxotere) y hormonoterapia en cáncer de próstata localizado de alto riesgo.

Ongoing
4
45
Europe
Docetaxel, Triptorelina, Goserelina, Leuprorelina, Taxotere, Casodex, Taxotere, Casodex
Grupo de Investigación en Oncología Médica del Hospital de Navarra
Pacientes con cáncer de próstata localizado de alto riesgo.
 
 
ChiCTR1900024958: Therapeutic Effect of Dienogest in Adenomyosis

Not yet recruiting
4
100
 
VISANNE 2MG Tablet once daily ;subcutaneous Goserelin acetate injections (3.6 mg/4 weeks, GoserelinAcetateSustained-ReleaseDepot)
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, no
adenomyosis
 
 
NCT05013242: Goserline Acetate VS Dienogest in Endometriosi

Recruiting
4
40
RoW
Zoladex, Gnrh, Visanne, Dienogest
Mansoura University
Endometriosis
11/21
12/21
2021-005184-42: Roll-over study to allow continued access to ribociclib

Ongoing
4
137
Europe
ribociclib, Zoladex, Tamoxifeno, LEE011, Film-coated tablet, Implant, Tablet, Kisqali, Goserelin, Tamoxifeno Farmoz
Novartis Pharma AG, Novartis Pharma AG
HR+, HER2- advanced or metastatic breast cancer, advanced or metastatic breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT04248621: Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Recruiting
4
164
RoW
Leuprorelin, Leuprorelin acetate, Goserelin, Goserelin acetate, Triptorelin, Triptorelin acetate, Degarelix, Degarelix acetate, Bicalutamide, Casodex, Flutamide, Niftolide, Maximum androgen blockade, LHRN agonist and antiandrogen
Wonju Severance Christian Hospital, Eulji University Hospital
Prostatic Neoplasms
04/22
12/22
ChiCTR2000034693: Multi-center, Prospective Study to Investigate the Efficacy and Safety of Zoladex (Goserelin Acetate) 10.8 mg Prior to Surgery in Premenopausal Women with Symptomatic Uterine Fibroids

Not yet recruiting
4
150
 
one depot of Zoladex 10.8mg
The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, AstraZeneca Investment (China) Ltd.,Co.
Uterine fibroids
 
 
ChiCTR2200059548: Comparison of clinical efficacy and incidence of uterine bleeding with different doses of GnRH-a in the treatment of adenomyosis in different periods of the menstrual cycle

Recruiting
4
180
 
A 10.8 mg goserelin acetate sustained-release implant is subcutaneously injected every 12 weeks, and a total of 1-2 injections are given according to the patient's condition ;A 3.6 mg goserelin acetate sustained-release implant is subcutaneously injected every 4 weeks, and a total of 3-6 injections are given according to the patient's condition
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, None
Adenomyosis
 
 
LEANORA, NCT04657679: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

Terminated
4
21
US
Ribociclib, KISQALI
Georgetown University, Medstar Health Research Institute, Breast Cancer Research Foundation, Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS)
Breast Cancer
10/23
10/23
ChiCTR2300076106: Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer

Recruiting
4
China
Airui'en (rezvilutamide) - Jiangsu Hengrui Pharma, goserelin acetate - Generic mfg.
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Prostate cancer
 
 
ARMOR, NCT06455969: Adaptions and Resiliency to Multi-Stressor OpeRations

Not yet recruiting
4
120
US
Goserelin 3.6 MG, Zoladex, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g), Estradiol / Levonorgestrel Transdermal System [Climara Pro], Placebo Patch
Bradley Nindl, U.S. Army Medical Research and Development Command
Musculoskeletal Injury, Hypogonadism
08/26
08/26
INTERSTELLAR, NCT05333328: OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Recruiting
4
418
RoW
Ovarian function suppression with endocrine treatments
Gangnam Severance Hospital, Seoul National University
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer, Premenopausal Breast Cancer, Node-positive Breast Cancer
01/28
01/33
NCT05161195 / 2021-005184-42: Roll-over Study to Allow Continued Access to Ribociclib

Recruiting
4
137
Europe, Japan, US, RoW
Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Breast Cancer
02/30
03/30
ARCH, NCT05700903: Contributions to Hypertension With Androgen Deprivation Therapy

Recruiting
4
228
US
Gonadotropin Releasing Hormone Agonists (GNRH), Leuprolide, Goserelin, Androgen receptor (AR) inhibitor, Bicalutamide, Flutamide, Enzalutamide, Placebo
University of Colorado, Denver
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
03/28
03/28
ACTRN12607000237482: A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate

Completed
3
800
 
Trans Tasman Radiation Oncology Group (TROG), National Health & Medical Research Council Project Grant
Prostate Cancer
 
 
2004-001984-22: Essai randomisé de phase III comparant l’association traitement hormonal + docétaxel au traitement hormonal seul dans les cancers de la prostate métastatiques

Ongoing
3
20
Europe
Taxotère, ZOLADEX®, ANANDRON®, Solution for infusion, Implant, Tablet, TAXOTERE®, ZOLADEX®, ANANDRON
Fédération Nationale des Centres de Lutte Contre le Cancer
L’utilisation précoce dans une situation d’androgènosensibilité d’une chimiothérapie active laisse envisager une meilleure efficacité à un stade plus précoce du cancer de la prostate métastatique, avec un volume tumoral a priori moins important et moins de clones résistants.
 
 
2011-001193-26: Efficacy of the Acino goserelin 3.6 mg implant that is administered twice in two months in patients with prostate cancer and examination of goserelin and hormone levels in the blood after administration of the Acino goserelin 3.6 mg implant and the Zoladex® 3.6 mg implant in a smaller subgroup of patients.

Ongoing
3
145
Europe
Goserelin 3.6 mg Implant, Zoladex 3.6 mg, Implant, Zoladex 3.6 mg
Acino Supply AG, Acino Supply AG
Locally advanced, recurrent, or metastatic carcinoma of the prostate indicated for endocrine therapy, Advanced prostate cancer, Diseases [C] - Cancer [C04]
 
 
2006-002600-33: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer

Ongoing
3
30
Europe
Zoladex, not applicable, Zoladex, Zoladex
International Breast Cancer Study Group (IBCSG), IBCSG
Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
 
 
2009-016200-23: An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days

Ongoing
3
40
Europe
Acino Goserelin 10.8 mg Implant, 30060,
Acino Supply AG
prostate cancer
 
 
2009-015881-71: An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of two new GnRH implants (AMW Goserelin 3.6 mg Implant and AMW Leuprorelin 3.6 mg Implant) applied every 28 days for 84 days

Ongoing
3
80
Europe
AMW Goserelin 3.6 mg Implant, AMW Leuprorelin 3.6 mg Implant, AMW Goserelin 3.6 mg Implant, AMW Leuprorelin 3.6 mg Implant,
AMW GmbH
prostate cancer
 
 
2010-018735-18: An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Goserelin 10.8 mg Implant) applied every 84 days for 168 days

Ongoing
3
40
Europe
AMW Goserelin 10.8 mg Implant, AMW Goserelin 10.8 mg Implant,
AMW GmbH
prostate cancer
 
 
2013-000798-59: Phase III, open-label, multi-centre study to investigate the movement, effect and safety of Zoreline 3.6 mg goserelin implant (Novalon) injected under skin, in women with confirmed endometriosis

Ongoing
3
142
Europe
Zoreline 3.6 mg goserelin, Implant in pre-filled syringe
Novalon S.A, Novalon S.A
Endometriosis, Endometriosis is a common condition where tissue that behaves like the lining of the womb (the endometrium) is found outside the womb., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT02003209: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Active, not recruiting
3
315
US
Aromatase Inhibition Therapy, Aromatase Inhibition, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cytology Specimen Collection Procedure, Cytologic Sampling, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Pertuzumab, 2C4, 2C4 Antibody, BCD-178, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar BCD-178, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, Pertuzumab Biosimilar TQB2440, Rhumab 2C4, rhuMAb2C4, RO4368451, TQB 2440, TQB-2440, TQB2440, Quality-of-Life Assessment, Quality of Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herclon, Hertraz, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Whole Breast Irradiation
National Cancer Institute (NCI), NRG Oncology
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
10/16
12/24
MONALEESA-7, NCT02278120 / 2014-001931-36: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Checkmark 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Dec 2020 - Dec 2020: 5 year median OS data in MONALEESA-7 study for HR+, HER2- metastatic breast cancer
Checkmark OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Nov 2020 - Nov 2020: OS data from MONALEESA-7 trial in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
Checkmark Subgroup analysis data from Monaleesa-3 and Monaleesa-7 trials for advanced breast cancer at ASCO 2020
More
Completed
3
672
Europe, Canada, US, RoW
Ribociclib, LEE011, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Novartis Pharmaceuticals
Advanced Metastatic Breast Cancer
08/17
04/23
RTOG 0534, NCT00567580: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Active, not recruiting
3
1792
Canada, US, RoW
PBRT, Prostate bed radiotherapy, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity modulated RT (IMRT), PLNRT, Pelvic lymph node radiotherapy, AA, flutamide, bicalutamide, LHRH agonist, leuprolide, goserelin, buserelin, triptorelin
Radiation Therapy Oncology Group, National Cancer Institute (NCI), Cancer and Leukemia Group B, NRG Oncology
Prostate Cancer
07/18
 
NCT00430183: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Active, not recruiting
3
788
Canada, US
docetaxel, LHRH agonist, leuprolide acetate OR, goserelin acetate, surgery
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, Southwest Oncology Group
Prostate Cancer
10/18
10/30
2019-000593-32: An experimental study in men with prostate cancer to investigate the drug Zoreline 10.8 mg on its effects on the human body and safety.

Not yet recruiting
3
142
Europe
Zoreline, Implant in pre-filled syringe
Novalon S.A., Novalon S.A.
Prostate cancer Prostatakrebs, Prostate cancer, Diseases [C] - Cancer [C04]
 
 
NCT02115282: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Checkmark Final OS data in combination with exemestane from E2112 trial for advanced HR+ breast cancer
May 2020 - May 2020: Final OS data in combination with exemestane from E2112 trial for advanced HR+ breast cancer
Hourglass Oct 2019 - Dec 2019 : Interim OS analysis from E2113 trial for advanced HR+, HER2- breast cancer in combination with exemestane
Checkmark Interim OS analysis of E2112 trial for advanced HR+, HER2- breast cancer in combination with exemestane
Oct 2019 - Oct 2019: Interim OS analysis of E2112 trial for advanced HR+, HER2- breast cancer in combination with exemestane
More
Active, not recruiting
3
608
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS-275, SNDX-275, Exemestane, Aromasin, FCE-24304, Goserelin, ICI-118630, Goserelin Acetate, ZDX, Zoladex, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
05/20
06/24
NCT00936390 / 2010-020825-42: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Active, not recruiting
3
1538
Canada, US
bicalutamide, flutamide, anti-androgen therapy, LHRH agonist (antagonist) therapy, leuprolide, goserelin, buserelin, triptorelin, degarelix, Dose-Escalated Radiation Therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
10/20
10/25
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
NCT01546987: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Active, not recruiting
3
239
Canada, US
GnRH agonist, LHRH analog, leuprolide, goserelin, buserelin, triptorelin, Gonadotropin-releasing hormone (GnRH) Agonist, LHRH agonist, Anti-androgen, flutamide, bicalutamide, androgen suppression, TAK-700, Radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Prostate Cancer
11/21
06/29
NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Completed
3
141
Japan, RoW
Palbociclib, Endocrine therapy
Kyoto Breast Cancer Research Network, Pfizer
Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
12/21
12/21
2022-000066-18: Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen. Onderzoek naar metastase gerichte therapie al dan niet in combinatie met hormoontherapie bij patiënten met een herval van prostaatkanker na initiële behandeling en maximum 5 metastasen.

Not yet recruiting
3
873
Europe
Implant in pre-filled syringe, Powder and solvent for solution for injection, Powder and solvent for suspension for injection, Capsule, soft, Zoladex 3,6 mg implant, Depo-Eligard 7,5 mg implant, Decapeptyl Sustained Release 11,25 mg, Zoladex Long Acting, 10,8 mg, implantaat, Depo-Eligard 45 mg implant, Depo-Eligard 22,5 mg implant, Decapeptyl Sustained Release 3,75 mg, Decapeptyl Sustained Release 22,5 mg, Xtandi 40 mg soft capsules
Universitaire Ziekenhuizen Leuven, Universitaire Ziekenhuizen Leuven
Oligorecurrent hormone-sensitive prostate cancer patients, Recurrent hormone-sensitive prostate cancer patients with maximum 5 metastasis, Diseases [C] - Cancer [C04]
 
 
NCT05110170: Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Completed
3
188
RoW
LY01005, Goserelin Acetate Sustained-Release Microspheres for Injection, ZOLADEX® 3.6 mg, Goserelin Acetate Implant 3.6 mg
Luye Pharma Group Ltd.
Breast Cancer
04/22
06/22
SHIP0804, NCT00664456: Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

Completed
3
421
Japan
Adjuvant therapy, Neoadjuvant therapy, Brachytherapy（iodine I 125）
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, The Jikei University School of Medicine
Prostate Cancer
04/22
06/23
AMEERA-5, NCT04478266 / 2020-001824-33: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Terminated
3
1068
Europe, Canada, Japan, US, RoW
Amcenestrant-matching placebo, SAR439859, Amcenestrant, Palbociclib, Ibrance, Letrozole, Goserelin, Letrozole-matching placebo
Sanofi
Breast Cancer
06/22
05/23
2021-006975-41: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía: un ensayo fase III aleatorizado, controlado, multicéntrico

Not yet recruiting
3
534
Europe
triptorelina equivalente, triptorelina (pamoato), leuprorelina, goserelina, Powder and solvent for prolonged-release suspension for injection, Powder and solvent for solution for injection, Powder and solution for solution for injection, Powder and solvent for suspension for injection in pre-filled syringe, Powder and solvent for solution for injection in pre-filled syringe, Implant in pre-filled syringe, Decapeptyl semestral, Decapeptyl trimestral, Eligard mensual, Eligard semestral, Eligard trimestral, Procrin Mensual, Procrin Semestral, Procrin Trimestral, Zoladex
GICOR, GICOR
Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy Terapia de deprivación androgénica de corta ó larga duración en combinación con radioterapia de rescate en pacientes con cáncer de próstata con recidiva bioquímica tras cirugía, prostate cancer cáncer de próstata, Diseases [C] - Cancer [C04]
 
 
NCT01674140: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Active, not recruiting
3
1939
US
anastrozole, Arimidex, everolimus, Afinitor, exemestane, Aromasin, goserelin acetate, Zoladex, letrozole, Femara, leuprolide acetate, Lupron, tamoxifen citrate, nolvadex, placebo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Breast Cancer
12/22
01/30
DELFINO, NCT03664895: Density Lowering Effect of "OFS Add on to TMX"( Trial)

Recruiting
3
224
RoW
Leuplin or zoladex
Seoul National University Hospital
Breast Cancer Invasive
12/24
12/24
NCT03137368: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

Enrolling by invitation
3
300
RoW
Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test, Tamoxifen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Pfizer
CYP2D6 Polymorphism
10/23
10/23
NCT03936218: Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Recruiting
3
94
RoW
Inj. Goserelin (Test) Subcutaneously, Goserelin, Inj. Zoladex (Reference) Subcutaneously, Zoladex
Eurofarma Laboratorios S.A.
Advanced Prostate Cancer
11/23
06/25
NCT03936933: Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer

Recruiting
3
68
RoW
Goserelin acetate 3.6 mg Injection, Goserelin acetate, ZOLADEX® 3.6mg Injection, Zoladex
Eurofarma Laboratorios S.A.
Breast Cancer
09/24
01/25
URONCOR 06-24, NCT05781217: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

Recruiting
3
534
Europe
triptorelin, goserelin, leuprorelin
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence, Androgen Deprivation Therapy, Metastases-free Survival
12/23
12/32
ASPAIT, NCT02914158: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Recruiting
3
680
RoW
Goserelin, Tamoxifen, Aromatase Inhibitors, Leuprolide, leuprolide acetate
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
12/23
12/25
PCS III, NCT00223145: Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone

Active, not recruiting
3
600
Canada
Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade, Bicalutamide 50 mg, Goserelin 10.8 mg
Abdenour Nabid, AstraZeneca
Prostate Cancer
12/23
12/23
NCT06447623: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Recruiting
3
184
RoW
Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant
Fudan University
Advanced Breast Cancer, HR+/HER2- Breast Cancer
02/27
02/29
NCT05438810: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Recruiting
3
312
RoW
FCN-437c,Fulvestrant,Goserelin acetate, Placebo,Fulvestrant,Goserelin acetate
Ahon Pharmaceutical Co., Ltd.
Advanced Breast Cancer, Female Breast Cancer
02/24
05/24
NCT02132390: Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Not yet recruiting
3
300
RoW
Goserelin, Zoladex, Toremifene
Peking Union Medical College Hospital
Breast Cancer, Chemotherapy Induced Amenorrhea, Ovarian Function Suppression
05/24
 
CASPAR, NCT04455750: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Active, not recruiting
3
61
US
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
05/24
09/26
NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
NCT05439499: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Recruiting
3
434
RoW
FCN-437c, Letrozole or anastrozole, Goserelin acetate, Placebo, Letrozole or anastrozole, Goserelin acetate
Ahon Pharmaceutical Co., Ltd.
Advanced Breast Cancer, Female Breast Cancer
09/24
03/25
PATHWAY, NCT03423199: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Active, not recruiting
3
180
Japan, RoW
Palbociclib, PD-0332991, Placebo, Tamoxifen, Goserelin
National Cancer Center, Japan, Pfizer, Korean Cancer Study Group
Breast Neoplasms
09/25
09/25
NCT01492972: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Recruiting
3
192
US
Radiation, Androgen Suppression Therapy, leuprolide, goserelin, buserelin, or triptorelin
Proton Collaborative Group
Prostate Cancer
12/25
 
NCT02535221: Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Recruiting
3
234
RoW
Goserelin+TAM+AI, Endocrine therapy, Epirubicin+CTX+5-Fu, Chemotherapy
Peking University
Breast Cancer
06/26
12/26
SPARKLE, NCT05352178: Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Recruiting
3
873
Europe
Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
Universitaire Ziekenhuizen Leuven
Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Disease, Oligometastasis, Hormone Sensitive Prostate Cancer
04/27
04/32
NCT05009290: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Recruiting
3
1256
RoW
SHR3680, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
10/27
10/31
S1802, NCT03678025: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
3
1273
Europe, US, RoW
Abiraterone, CB 7598, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Histrelin Acetate, Supprelin, Vantas, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Radical Prostatectomy, Prostatovesiculectomy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Decapeptyl, Detryptoreline
SWOG Cancer Research Network, National Cancer Institute (NCI)
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/28
10/31
ERADICATE, NCT04484818: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The Study

Active, not recruiting
3
27
US
Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Prostate Carcinoma
05/28
05/28
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Recruiting
3
766
RoW
Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist
Fudan University
Breast Cancer
05/28
05/31
ADJUVANT WIDER, NCT05827081: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Suspended
3
3100
RoW
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Novartis Pharmaceuticals
Early Breast Cancer
09/29
09/30
CARLHA-2, NCT04181203: Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Recruiting
3
490
Europe
Apalutamide, ARN-509, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa), leuprolide, goserelin, triptorelin acetate
UNICANCER, Janssen Pharmaceutica
Prostate Cancer
09/28
12/33
PRIMORDIUM, NCT04557059 / 2019-002957-46: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Recruiting
3
412
Europe, US, RoW
Radiotherapy, LHRHa, Apalutamide, JNJ-56021927
Janssen Pharmaceutica N.V., Belgium
Prostatic Neoplasms
08/29
08/29
OFSET, NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting
3
3960
US
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer
01/32
07/34
GUIDANCE, NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Recruiting
3
2050
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma
04/32
04/37
INDICATE, NCT04423211: Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
3
804
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Degarelix, FE200486, Firmagon, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Proton Therapy, IMPT, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Relugolix, N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, TAK 385, TAK-385, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline, Volume Modulated Arc Therapy, VMAT, Volumetric Modulated Arc Therapy (procedure)
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
12/32
12/32
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
SHPD002, NCT02221999: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

Active, not recruiting
2/3
250
RoW
Paclitaxel, Taxol, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole
RenJi Hospital
Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
01/19
01/29
NCT05253066: Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Not yet recruiting
2/3
130
NA
Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
Shengjing Hospital
Breast Neoplasms
07/22
01/25
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
NCT06009627: Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Recruiting
2/3
119
RoW
Dalcelli、Exemestane、Gosserine, Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
03/25
09/26
NCT02685397: Management of Castration-Resistant Prostate Cancer With Oligometastases

Recruiting
2/3
130
Canada
Leuprolide Acetate, Eligard, Lupron, Goserelin Acetate, ZOLADEX, Triptorelin, Trelstar, Enzalutamide, Xtandi, Stereotactic Body Radiation Therapy, SBRT
Sir Mortimer B. Davis - Jewish General Hospital
Castration-resistant Prostate Cancer Patients With Oligometastases
04/25
08/41
VA STARPORT, NCT04787744: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Recruiting
2/3
464
US
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
VA Office of Research and Development
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
07/25
12/25
NRG-GU002, NCT03070886: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Active, not recruiting
2/3
175
Canada, US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard, Goserelin Acetate, ZDX, Zoladex, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Nilutamide, Anandron, Nilandron, RU-23908
NRG Oncology, National Cancer Institute (NCI)
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
05/26
05/31
ACTRN12607000082404: A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomy

Not yet recruiting
2
15
 
Urology Department The Royal Melbourne Hospital, The Royal Melbourne Hospital
Prostate cancer
 
 
ACTRN12619001117101: BCT 1901 (CAPTURE): Women or men with oestrogen receptor positive, HER2 negative advanced breast cancer and PIK3CA mutant circulating DNA will be randomised to evaluate treatment with alpelisib plus fulvestrant compared with capecitabine on progression free survival.

Recruiting
2
66
 
Breast Cancer Trials, National Health and Medical Research Council
Advanced Breast Cancer
 
 
CTR20201637: A clinical study to evaluate the safety and preliminary efficacy of FCN-437c in the treatment of female patients with ER-positive, HER2-negative advanced breast cancer

Completed
2
60
China
FCN-437 - Fosun Pharma
Chongqing Fuchang Pharmaceutical Research Co., Ltd./Shanghai Fushang Huichuang Pharmaceutical Research Co., Ltd.
ER-positive, HER2-negative advanced breast cancer
 
 
AMBER, jRCTs051220133: JBCRG-M08( trial)

Recruiting
2
150
Japan
Verzenio (abemaciclib) - Eli Lilly, anastrozole - Generic mfg., fulvestrant - Generic mfg., letrozole - Generic mfg., goserelin acetate - Generic mfg., leuprorelin (CKD-841) - Chong Kun Dang
Osaka University Hospital, Eli Lilly Japan K.K
Hormone receptor-positive, HER2-negative inoperable or recurrent breast cancer
 
 
NCT00544830: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruiting
2
29
US
Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Goserelin Acetate, ZDX, Zoladex, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
City of Hope Medical Center, National Cancer Institute (NCI)
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
03/11
12/24
ChiCTR-ONC-13003946: A Phase II clinical study of Goserelin combine with Exemestane in premenopausal women with metastatic breast cancer

Completed
2
30
 
Goserelin 3.6mg/Month combine with Exemestane 25mg Qd
Department of Medical Oncology, Cancer Institute/Hospital, CAMS and PUMC; Level of the institution：, Department of Medical Oncology, Cancer Institute/Hospital, CAMS and PUMC
breast cancer
 
 
2014-000273-39: Trial investigating hormone injections, external beam radiotherapy and intravenous radionuclide injection in patients with advanced prostate cancer.

Ongoing
2
30
Europe
Solution for injection, Implant, , Powder and solvent for suspension for injection, Powder for suspension for injection, Xofigo 1000 kBq/mL solution for injection, Zoladex 3.6mg implant, Zoladex LA 10.8mg implant, Prostap SR DCS, Prostap 3 DCS, Decapeptyl SR 3mg, Decapeptyl SR 11.25mg
Belfast Health and Social Care Trust, Bayer PLC
Metastatic castration sensitive prostate cancer, Advanced prostate cancer, Diseases [C] - Cancer [C04]
 
 
ASN-002-IL, NCT02107391 / 2004-002708-13 / ACTRN12619001298101: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

Completed
2
63
RoW
Dendritic Cells DCVAC/PCa, Leuprolide acetate, Lupron, Goserelin Acetate, Zoladex
SOTIO a.s., Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome (BCNS)
12/15
06/16
2008-007028-25: A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex)

Ongoing
2
72
Europe
Decapeptyl SR, Zoladex, Decapeptyl 3mg SR, Zoladex, Decapeptyl 3mg SR, Zoladex
University Hospitals Bristol NHS Foundation Trust
Enrolled patients will be those with a diagnosis of prostate cancer who require radiotherapy to the prostate, with medical castration by means of Luteneising Hormone Releasing Hormone analogue (LRHRa) injections before radiotherapy commences.
 
 
2015-001756-30: A study in males with prostate cancer performed in several centers to assess the blood levels after injection of two subcutaneous implants containing 10.8 mg goserelin

Ongoing
2
38
Europe
Zoreline 10.8 mg implant, Zoladex® LA, Zoladex® LA
Novalon S.A., Novalon S.A.
prostate cancer
 
 
2016-001087-11: CIBRAC - Chemoprevention in BRCA1 mutation carriers

Ongoing
2
12
Europe
Tamoxifen, Anastrazole, Goserelin, Tablet, Implant, Zoladex
Belfast Health and Social Care Trust, Cancer Research UK
BRCA1 mutation carrier Breast Cancer, Hereditary Breast Cancer, Diseases [C] - Cancer [C04]
 
 
2017-000154-19: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer

Not yet recruiting
2
90
Europe
Alpelisib, BYL719, Tablet, Solution for injection, Implant in pre-filled syringe, Powder and solvent for solution for injection, FASLODEX, ZOLADEX, ENANTONE
UNICANCER, Novartis
PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy., Breast cancer, Diseases [C] - Cancer [C04]
 
 
ChiCTR-IPC-14005453: A Randomized, Open-label, Phase II Trial of Neoadjuvant Docetaxel Combined with Goserelin for Very High-risk Locally Advanced Prostate Cancer Before Radical Prostatectomy

Not yet recruiting
2
132
 
Neoadjuvant Docetaxel+Goserelin+Radical Prostatectomy ;Radical Prostatectomy
Department of Urology, Fudan University Shanghai Cancer Center; Department of Urology, Fudan University Shanghai Cancer Center, Fudan University Shanghai Cancer Center Prospective Clinical Trial Specialized Fundation
Prostate Cancer
 
 
PREDIX LumA, NCT02592083: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

Active, not recruiting
2
10
Europe
Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin, Tamoxifen, Letrozol or Anastrozol or Exemestane, Zoladex, Palbociclib, Ibrance
Thomas Hatschek
Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor
02/19
02/29
NCT02278185: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Active, not recruiting
2
19
US
Enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, histrelin acetate, Supprelin, Vantas, triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, D-TRP-6-LHRH, Decapeptyl, TRIP, degarelix, ASP3550, FE200486, Firmagon
University of Colorado, Denver
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
04/19
04/25
NCT02430480: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Active, not recruiting
2
39
US
Goserelin, Zoladex, Enzalutamide, ASP-9785, mpMRI, multi-parametric magnetic resonance imaging
National Cancer Institute (NCI)
Prostate Cancer
12/19
06/25
NCT03007979: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed
2
55
US
Palbociclib, Ibrance, Letrozole, Femara, Fulvestrant, Faslodex, Optional research biopsy, Goserelin, Zoladex, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Washington University School of Medicine, Pfizer
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
03/20
03/23
PETREMAC, NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the Trial

Active, not recruiting
2
200
Europe
Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide
Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca
Breast Cancer
06/20
06/30
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
NCT04536467: Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

Enrolling by invitation
2
80
RoW
Goserelin, zoladex, Chemotherapy, chemotherapy protocols
Beni-Suef University
Premature Ovarian Failure
12/20
11/24
2018-003832-57: Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

Not yet recruiting
2
166
Europe
Durvalumab, Olaparib, Fulvestrant, Goserelin, MEDI4736, Solution for infusion, Tablet, Solution for injection, Implant in pre-filled syringe, Faslodex, ZOLADEX
UNICANCER, Laboratories AstraZeneca
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status., ER-positive and HER2-negative metastatic or locally advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT02058706: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Completed
2
71
US
enzalutamide, MDV3100, selective androgen receptor modulator MDV3100, XTANDI, bicalutamide, Casodex, CDX, orchiectomy, leuprolide acetate, Enantone, LEUP, Lupron, Lupron Depot, goserelin acetate, ICI-118630, ZDX, Zoladex, laboratory biomarker analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
03/21
03/21
NCT02742675: Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Active, not recruiting
2
200
RoW
Bicalutamide, Casodex, goserelin acetate, Zoladex, flutamide, Eulexin, leuprolide acetate, Enantone, triptorelin, Diphereline, Definitive Treatment
Fudan University
Prostate Cancer
03/21
03/23
NeoGONT, NCT03444025: Neoadjuvant Goserelin for Triple Negative Breast Cancer

Not yet recruiting
2
180
NA
Goserelin, Zoladex
Kasr El Aini Hospital
Breast Cancer Triple Negative
03/21
03/23
NCT04356430: Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer

Active, not recruiting
2
75
RoW
Abiraterone Acetate, Prednisone, Goserelin 10.8 mg
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
03/21
12/23
 

Download Options